Show simple item record

dc.contributor.advisorSzegezdi, Eva
dc.contributor.authorO' Reilly, Paul
dc.description.abstractTRAIL is a member of the TNF family of cytokines which can selectively induce apoptosis in cancerous cells. For this reason recombinant TRAIL is being considered for the treatment of cancer. During their development cancer cells disengage pivotal sections of the machinery required for apoptosis. This is also the case for the TRAIL pathway. Concurrently 50-60% of tumours are known to be resistant to TRAIL. Additionally reports found that TRAIL can initiate NF-kB -pro-survival pathways in resistant cell lines which may promote tumour aggression. Therefore a reliable biomarker that can identify responsive patients is needed. Biomarker discovery is often based on the identification of differentially expressed genes from transcriptome studies. In these analyses the threshold is a minimum arbitrary level (e.g. two fold induction.) in the majority of samples. This gene-by-gene approach cannot assess interaction between genes or proteins. . Minimal forays have been made into identifying genes or proteins which potentially influence each other, i.e. their combined presence or ratio correlates stronger with a given phenotype. These expression ratios, even if they are not robustly overexpressed or repressed, may better identify decisive interactions and predict response. Here we show that by utilizing classification trees we could identify a panel of genes which could predict sensitivity to TRAIL with a high degree of sensitivity and specificity. In addition we identify the caspase-8/Bcl-2 protein expression ratio as a predictive biomarker for sensitivity to TRAIL. Both of these biomarkers perform better than other classifiers of TRAIL sensitivity.en_US
dc.subjectNatural Sciencesen_US
dc.titleIdentification of decisive molecular interactions regulating resistance to apoptosis in tumour cellsen_US
dc.contributor.funderScience Foundation Ireland (SFI)en_US
dc.local.noteChemotherapeutic treatments have side effects associated with them. These range from hair loss to nausea. TRAIL does not cause these symptoms. Unfortunately nearly 60% of all tumours are resistant to TRAIL. Therefore there is a need for a biomarker which could accurately predict whether a patient would positively respond to TRAILen_US

Files in this item

Attribution-NonCommercial-NoDerivs 3.0 Ireland
This item is available under the Attribution-NonCommercial-NoDerivs 3.0 Ireland. No item may be reproduced for commercial purposes. Please refer to the publisher's URL where this is made available, or to notes contained in the item itself. Other terms may apply.

The following license files are associated with this item:


This item appears in the following Collection(s)

Show simple item record